Kura Oncology, Inc.
Bridged bicyclic inhibitors of menin-MLL and methods of use

Abstract:

The present disclosure provides compounds of Formula (I-E) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. ##STR00001##